The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drugs at a Glance, Part 2: Psoriasis

Rheumatology Drugs at a Glance, Part 2: Psoriasis

May 17, 2019 • By Mary Choy, PharmD, BCGP, FASHP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
  • Fatal hepatosplenic T cell lymphoma (HSTCL) has occurred postmarketing in adolescent and young adult inflammatory bowel disease (IBD) patients treated with TNFi’s.

Warnings & Precautions

You Might Also Like
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
Explore This Issue
May 2019
  • Do not start adalimumab during an active infection. If an infection develops, monitor carefully, and stop adalimumab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on adalimumab, consider empiric anti-fungal therapy for those who reside in or travel to regions where mycoses are endemic.
  • The incidence of malignancies was greater in adalimumab-treated patients than in the control groups.
  • Anaphylaxis or serious allergic reactions may occur.
  • Hepatitis B virus (HBV) reactivation can occur. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop adalimumab and begin anti-viral therapy.
  • Demyelinating disease exacerbation, or new onset, may occur.
  • Cytopenias, pancytopenia—advise patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on adalimumab. Consider discontinuation of therapy in patients with confirmed significant hematologic abnormalities.
  • Heart failure, worsening or new onset, may occur.
  • Lupus-like syndrome—stop adalimumab if syndrome develops.

Dosage & Administration

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Adalimumab is administered by subcutaneous injection. The recommended dose is an initial dose of 80 mg, followed by 40 mg every other week starting one week after the initial dose.

Commentary: The approval of adalimumab for plaque psoriasis was based on two pivotal clinical trials that had enrolled more than 1,400 patients. Nearly three in four patients achieved at least a PASI 75 at Week 16 of treatment vs. placebo. The most common adverse reactions (≥10%) are infections (e.g., upper respiratory, sinusitis), injection-site reactions, headache and rash.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Certolizumab pegol (Cimzia):14 injection

Drug class: DMARD, TNFi

Boxed warning: Refer to *ISI (above)

Warnings & Precautions

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  • Do not start certolizumab during an active infection. If an infection develops, monitor carefully, and stop certolizumab if the infection becomes serious.
  • Invasive fungal infections—for patients who develop a systemic illness on certolizumab, consider empiric anti-fungal therapy for those who reside in or travel to regions where mycoses are endemic.
  • Cases of lymphoma and other malignancies have been observed in patients receiving TNFi’s.
  • Heart failure, worsening or new onset, may occur.
  • Anaphylaxis or serious allergic reactions may occur.
  • HBV reactivation can occur. Test for HBV infection before starting certolizumab. Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop certolizumab and begin anti-viral therapy.
  • Demyelinating disease, exacerbation or new onset, may occur.
  • Cytopenias, pancytopenia—advise patients to seek immediate medical attention if symptoms develop, and consider stopping certolizumab.
  • Lupus-like syndrome—stop certolizumab if syndrome develops.

Dosage & Administration

Certolizumab is administered by sub­cutaneous injection. The recommended initial dose is 400 mg (given as two subcutaneous injections of 200 mg) every other week. For some patients (with body weight ≤90 kg), a dose of 400 mg (given as two subcutaneous injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg every other week may be considered.

Commentary: The U.S. Food and Drug Administration (FDA) approval was based on three clinical trials that enrolled over 1,000 patients. The results showed that patients had significant improvement in psoriasis symptoms through Week 48 in adults who received certolizumab compared with placebo. The most common adverse reactions (≥7%) are upper respiratory tract infection, rash and urinary tract infection.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions, Drug Updates Tagged With: adalimumab, apremilast, brodalumab, Certolizumab Pegol, etanercept, guselkumab, guttate psoriasis, infliximab, inverse psoriasis, ixekizumab, Psoriatic Arthritis, psoriatic erythroderma, pustular psoriasis, Rheumatic Drugs at a Glance, secukinumab, tildrakizumab, ustekinumab, vulgar psoriasisIssue: May 2019

You Might Also Like:
  • Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
  • Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis
  • Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4
  • Rheumatology Drug Updates: Etanercept for Pediatric Plaque Psoriasis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)